Genevie, L., Struening, E.L., Kallos, J.E., Geiler, I., Muhlin, G.L., and Kalplan, S. (1988). Urban community reaction to health facilities in residential areas: Lessons from the placement of methadone facilities in New York City. International Journal of the Addictions, 23(6), 603-616.
Gold, M.R., Siegel, J.E., Russell, L.B., and Weinstein, M.C. (Eds.). (1996). Cost-effectiveness in health and medicine. New York: Oxford University Press.
Greenstein, R.A., O’Brien, C.P., Woody, G., Long, M., Coyle, G., Grabowski, J., and Vittor, A. (1981). Naltrexone: A short-term treatment alternative for opiate dependence. American Journal of Drug and Alcohol Abuse, 8(3), 291-300.
Griesler, P.C., Kandel, D.B., and Davies, M. (2002). Ethnic differences in predictors of initiation and persistence of adolescent cigarette smoking in the National Longitudinal Survey of Youth. Nicotine and Tobacco Research, 4(1), 79-93.
Harwood, H., Fountain, D., and Livermore, G. (1998). The economic costs of alcohol and drug abuse in the United States, 1992-1998 . (NIH Pub. No. 98-4327). Washington, DC: National Institute on Drug Abuse.
Hieda, Y., Keyler, D.E., Vandevoort, J.T., Kane, J.K., Ross, C.A., Raphael, D.E., Niedbalas, R.S., and Pentel, P.R. (1997). Active immunization alters the plasma nicotine concentration in rats. Journal of Pharmacology and Experimental Therapeutics, 283(3), 1076-1081.
Hieda, Y., Keyler, D.E., Ennifar, S., Fattom, A., and Pentel, P.R. (2000). Vaccination against nicotine during continued nicotine administration in rats: Immunogenicity of the vaccine and effects on cocaine distribution to brain. International Journal of Immunopharmacology, 22(10), 809-819.
Institute of Medicine. (1998). Bridging the gap between practice and research: Forging partnerships with community-based drug and alcohol treatment. Committee on Community-Based Drug Treatment. S. Lamb, M.R. Greenlick, and D. McCarty (Eds.). Washington, DC: National Academy Press.
Johnson, B.D., Rosenblum, A., and Kleber, H. (2003). A new opportunity to expand treatment for heroin users in New York City: Public policy challenges for bringing buprenorphine into drug treatment programs and general medical practice. White Paper for New York City Department of Health and Mental Hygiene. Available: http://www.nyc.gov/html/doh/pdf/public/dmh/whitepaper.pdf [August 21, 2003].
Kabat, G.C. (2003). Fifty years’ experience of reduced-tar cigarettes: What do we know about their health effects? Inhalation Toxicology, 15(11), 1059-1102.
Kantak, K.M., Collins, S.L., Bond, J., and Fox, B.S. (2001). Time course of changes in cocaine self-administration behavior in rats during immunization with the cocaine vaccine IPC-1010. Psychopharmacology, 153(3), 334-340.
Keyler, D.E., Hieda, Y., St. Peter, J., and Pentel, P.R. (1999). Altered disposition of repeated nicotine doses in rats immunized against nicotine. Nicotine Tobacco Research, 1, 241-249.
Kirchmayer, U., Davoli, M., and Verster, A. (2004). Naltrexone maintenance treatment for opioid dependence. In The Cochrane Library (Issue 1). Chichester, England: John Wiley & Sons.
Kleiman, M.A.R. (2004). Costs and benefits of immunotherapies or depot medications for the treatment of drug abuse. In H.J. Harwood and T.G. Myers (Eds.), New treatments for addiction: Behavioral, ethical, legal, and social questions. National Research Council and Institute of Medicine. Washington, DC: The National Academies Press.
Klein, M. (1998). Research issues related to development of medications for treatment of cocaine addiction. Annals of the New York Academy of Sciences, 844, 75-91.
Klesges, L.M., Johnson, K.C., Somes, G., Zbikowski, S., and Robinson, L. (2003). Use of nicotine replacement therapy in adolescent smokers and nonsmokers. Archives of Pediatrics and Adolescent Medicine, 157, 517-522.